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A simple quantitative method for the measurement of 
leukotaxis in vivo is described. Duplicate skin chambers 
are placed over tape-stripped skin with 50% autologous 
serum-50% Hank's balanced salt solution as the attrac-
tant. Neutrophils predominate throughout 24 hr in this 
method with no change to mononuclear cells. A recom-
mended modification of our original method is that 
chambers are sampled and removed after 8 hr rather 
than 24 hr since the majority of leukocyte migration 
occurs within the first 8 hr. 
Analysis of serum factors showed that heat-inactiva-
tion of the serum (56°C for 30 min) had no effect. How-
ever, depleting platelets or C5 from the serum removed 
approximately 90% of chemotactic activity for human 
neutrophils in vivo. Platelets, presumably through activ-
ity of their granules, enzymatically cleaves C5a from C5 
in plasma. We conclude that C5a, after cleavage from C5, 
accounts for the majority of chemattractant activity in 
vivo. 
We recently reported a quantitative method of investigating 
migration of leukocytes to skin sites that avoided skin abrasion 
and left the basal lamina of the epidermis and the dermal blood 
vessel walls intact [1]. The quantitative data obtained and the 
lack of discomfort to the subjects studied were distinct advan-
tages over previous methods [2-4]. Our initial studies assayed 
the chamber after 24 hr of exposure to an attractant (50% 
autologous serum) in order to compare our method to those 
reported before. The purpose of this report is to describe our 
observations on the temporal kinetics of this response and the 
serum requirements for the attractant. 
Several proteins in normal human blood have been found to 
be capable of stimulating directional movement of neutrophils. 
Manuscript received August 15, 1978; accepted for publication No~ 
vember 28, 1978. 
Supported in part by a grant AI-12028 from the National Institutes 
of Health, a training grant I-T32-AI07166 from the National Institutes 
of Health, a grant l-ROI-A1l317l from the National Institutes of 
Health, Public Health Service Research Grant CA-15564-03 from the 
National Cancer Institute, Environmental Protection Agency Grant 
R803968-01-0, a Biological-Medical Award from the Swiss Academy of 
Medical Sciences, by funds provided by the House Bill #1578 of the 
State of Colorado Legislature (Sickle Cell Anemia Treatment and 
Research Center), and by a General Research Support Grant 5-S01-
RR05357 from the United States Public Health Service. 
Salary support for M. B. Harris was provided through a fellowship 
from the National Program for Dermatology. 
Presented in part at the Annual Society for Investigative Dermatol-
ogy Meeting in San Francisco, May 1978. 
Reprint requests to: Dr. William 1. Weston, University of Colorado 
Medical Center, 4200 East Ninth Avenue, Denver, Colorado 80262. 
Abbreviations: 
CF A: complete Freund's adjuvant 
HBSS: Hank's balanced salt solution without phenol red 
HSA: human serum albumin 
PPP: platelet-poor plasma 
PPS: platelet-poor serum 
Studies of the complement system have demonstrated activity 
in C3a [5,6], C5a [7,8], and the C5b-C6-C7 complex [9-11]. 
Other proteins which have chemotactic activity include fibrin-
ogen and fibrin cleavage products [12,13] and kallikrein (plas-
minogen activator) [14,15]. This particular property of these 
proteins has generally been demonstrated in vitro by means of 
a modification of the Boyden chamber technique. The com-
'plexities of protein system interactions h ave made in vivo 
evaluation of chemotaxis technically difficult. 
In vitro studies with highly purified components h ave pointed 
to C5a, a product of C5 proteolysis, as a far more efficaceous 
chemattractant compared to C3a [16,17]. C5a may be generated 
in a variety of ways. Neutrophils [18],- macrophages [19], and 
platelets [20] all contain proteolytic enzymes within their lyso-
somal granules capable of protease activity against C5, presum-
ably resultin g in C5a fragments. Activation of either the clas-
sical or alternative complement systems will generate C5a 
through enzymes mediated through C3b that in turn cleave C5 
[21]. Injured tissue in many diverse conditions can activate 
complement-dependent chemotaxis [22-25]. 
In this study we further document th e primary role of C5a in 
neutrophil chemotaxis using an in vivo system. We also confirm 
the ability of platelets to generate chemotactic activity during 
the normal clotting in vitro. 
MATERIALS AND 'METHODS 
Healthy human volunteers, after informed consent, were asked to 
donate 10 ml of blood by peripheral venipuncture. Whole blood was 
coagulated and sedimented at 37°C for 1 hr, then centrifuged at 20 X 
g for 15 min and serum withdrawn. Serum was diluted with sterile 
Hank's balanced salt solution without phenol red (HBSS) (ColoradO 
Serum Company, Denver, Colorado) for use in the chambers. 
Two sites on the volar surface of the forearm were pre hydrated for 
1 hr with water to facilitate tape-stripping. The sites were cleaned with 
Betadine scrub and 70% ethyl alcohol. Aseptic technique was employed 
in an attempt to diminish bacterial growth and resultant leukotaxis due 
to bacterial products on the occluded area. Tape-stripping was done 
over a template with 1 cm" skin area prepared. Stripping was complete 
when a glistening surface was achieved. Plastic chambers of our design 
[1] were placed over the tape-stripped areas and fIlled with the attrac-
tant to a 2 ml total volume. 0.2 ml samples were aspirated from each of 
the duplicate chambers at the indicated intervals and the cells were 
counted in a ' hemocytometer. All samples were cytocentrifuged and 
stained with the standard Wright's stain for differential WBC counts. 
Results were reported as leukocytes/cm2 skin/24 hr, unless noted 
differently. 
Control Studies 
Five volunteers had duplicate chambers containing HBSS only sam-
pled at 8 and 24 hr. 
Cell Kinetics 
Nine volunteers had duplicate chambers containing 50% autologous 
serum-50% HBSS as the attractant and were sampled at 4, 8 and 24 
hr. 
Serum Requirements 
Autologous serum was heat-inactivated at 56°C for 30 min to deter-
mine whether attractant in this system was heat labile. Seven vol un-
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teers than had duplicate chambers applied with 50% heat-inactivated 
serum-50% HBSS as the attractant and were assayed at 24 hr. Eight 
other volunteers had single chambers applied with this same attractant 
and were assayed at 8 hr. These were compared to HBSS. 
To determine the amount of autologous serum attractant necessary, 
5 volunteers had chambers containing 10% and 1 % serum diluted with 
HBSS and sampled after 24 hr. Eight volunteers and 7 volunteers had 
0.1 and 0.01% autologous serum dilutions in HBSS respectively, used 
as the attractant and were sampled at 8 yr. 
Bacterial cultures on blood agar have been performed on 104 con-
secutive chambers at the time of sampling and incubated at 37°C on 
blood agar. 
Data were evaluated by a 1 or 2-tailed t-test where appropriate, and 
by a one-way analysis of variance with the Student-Newman-Keuls 
procedure where appropriate. 
Discrepancies between number of chambers applied and those sam-
pled are due to the occasional problem of leakage. 
Analysis of Platelet and GSa Activity 
Plastic chambers placed over tape-stripped skin contained the che-
rnattractants. All serum samples were assayed in duplicate, sampled at 
B hr and counted in a hemocytometer. 
Unactivated serum was obtained from platelet poor plasma. Whole 
blood was first collected from normal human volunteers by clean 
venipuncture using refrigerated sterile plastic syringes. The blood was 
placed in ice cold sterile plastic test tubes and centrifuged immediately 
at 4500 g at 2°C for 20 min. The plasma was carefully separated into a 
sterile glass test tube yielding platelet-poor plasma (PPP) . This was 
then allowed to clot for 2 hr in a sterile glass test tube. The fibrin clot 
was sterilely removed by centrifugation. 
This unactivated serum was designated platelet poor serum (PPS). 
To determine if PPS had a diminished chemotaxis ability, each of 8 
volunteers had 3 chambers applied [1], 1 containing 50% autologous 
normal serum obtained from whole blood clotted for 1 hr at 25°C and 
2 con~aining 50% autologous PPS. The diluent used was HBSS. Cham-
bers were sampled for cell counts at 8 hr. 
In the subsequent experiment autologous PPS was used as the 
substrate from which C5 or albumin was immunoabsorbed in the 
method outlined below. 
Whole blood was drawn from 8 volunteers and PPS was prepared 
from each sample. Each sample was then divided into 3 aliquots. The 
first was depleted of C5 by immunoabsorption with monospecific anti-
C5; the second was depleted of albumin by similar monospecific im-
rnunoabsorption; and the third aliquot remained as PPS. 
The C5 depleted and albumin depleted aliquots were then activated 
by mixing for 45 min at 37°C with 0.2 rnl Zymosan susp./rnl serum 
[22,23]' The Zymosan was then removed by centrifugation. Each aliquot 
was diluted to 50% with HBSS and finally sterilized by filtration 
through 0.22 11 Millipore fIlter and cultured on blood agar prior to 
storage. All serum preparations were stored in sterile plastic test tubes 
at -70°C for a maximum of 4 days prior to use . 
Each of 8 volunteers had 3 chambers applied with 50% autologous 
serum treated in 3 different ways; PPS, PPS with C5 depletion and 
Zymosan activation, and PPS with albumin depletion and Zymosan 
activation. ALI chambers were sampled at 8 hr. 
Preparation of Immunoabsorbed Serum 
Purified human C5 was donated by Dr. H. J. Muller-Eberhard, La 
Jolla, California and was isolated as previously described [28]. · The 
preparation contained a single protein migrating as a globulin on 
immunoelectrophoresis using a potent goat anti-whole human serum 
(Hyland Laboratories, Costa Mesa, California) . C5 was diluted in 0.15 
M NaCI to a protein (Folin-Lowry) concentration of 130 ILg/ rnl and 
emulsified with an equal volume of complete Freund's adjuvant (CFA). 
A goat was initially injected with 65 Ilg of C5 protein in each popliteal 
lymph node while under general anesthesia. Subsequent injections of 
the same amount of C5 in CF A were made intradermally and intra-
muscularly at monthly intervals X 4 beginning 2 weeks after primary 
immunization. The antiserum was monospecific for C5 by Ouchterlony 
analysis, immunoelectrophoresis and single radial immunodiffusion us-
ing whole human serum. The IgG fraction was purified chromatograph-
ically on DEAE 52 (Pharmacia, Piscataway) . One mg of this isolated 
IgG precipitated 89 Ilg of human C5 as determined by radial immuno-
diffusion. 
The anti-C5 immunoabsorbent was prepared using 100 mg of goat 
IgG and 800 mg Sepharose 2B as described [28]. A rabbit antiserum to 
human serum albumin (HSA) was prepared, the IgG fraction isolated 
and linked to Sepharose 2B as outlined above. This immunoabsorbent 
served as a negative control for the procedures outlined. 
RESULTS 
All volunteers experienced little or no discomfort with the 
chambers in place. All sites healed without scarring, and the 
occasional slight postinflammatory hyperpigmentation gener-
ally resolved within 3 to 4 weeks. 
Routine bacterial cultures of consecutive chambers sampled 
at 24 hr showed only 4 of 104 were contaminated. Staphylococ-
cus aureus or gram negative rods were found in these 4. None 
of the 8-hr samples were contaminated. The 4 cultures with 
bacterial growth were derived from chambers containing only 
the HBSS control sampled at 24 hr, and comprised 4 out of the 
5 chambers in this group showing minimal leukocyte migration 
(Fig 2). This migration may have been stimulated by the 
products of bacterial contamination. The remaining 6 control 
chambers were sterile at 24 hr. 
Differential counts of migrating leukocytes averaged 98% 
neutrophils, with a range of 95% to 100% neutrophils. This 
predominance of neutrophils is slightly higher than reported 
previously [1], since these chambers were samples at 8 hr rather 
than at 24 hr. 
Evaluation of the migration kinetics with 50% autologous 
serum as the attractant showed that the mean leukocyte counts 
at 4, 8, and 24 hr were 2.2 X 104 , 4.1 X 10' , and 3.8 X 106 
respectively. The 95% confidence intervals for the mean are 
shown in Fig 1. A considerably slower rate of migration into the 
chamber can be seen to occur after 8 hr. This would suggest 
that the major part of leukocyte migration has occurred in the 
first 8 hr. 
Studies of the dilution requirements for serum as an attrac-
tant, (Fig 2) show 10% and 1 % dilutions to be less potent 
attractants than 50% serum at 24 hr. Analysis of variance with 
the Student-Newman-Keuls procedure shows significance at 
the 0.01 level for the 50% serum only. 
Autologous serum dilutions of 50%,0.1 % and 0.01 % were also 
compared to HBSS control as leukocyte attractants at 8 hr. 
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FIG 1. Temporal relationship of neutrophil migration into skin 
chambers. Note that most migration occurs within the first 8 hr. 
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EFFECTS OF SERUM DILUTION 
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FIG 2. Effects of serum dilution on neutrophil migration into skin 
chambers means and standard deviation are shown above. Note that at 
24 hr there is some migration to media HBSS alone. 
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FIG 3. Effects of serum dilution at 8 hr. 0.1% and 0.01% serum 
induce some leukocyte migration but each are 10 and 100 times less 
than 50% serum respectively. 
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The means and standard deviations are shown in Fig 3. Analysis 
of variance shows the 50% serum to be significantly more potent 
an attractant (p < .01). More dilute serum stimulated leukocyte 
migration but quite variably and over a wide range. This.may 
in part be due to the possible measurement error in the hIghlY 
diluted groups. . 
The results of heat treatment of 50% autologous serum on Its 
effectiveness as a leukocyte attractant at 8 and 24 hr are shown 
in the Table. A 2-tailed t-test with pooled variance shows n~ 
significant difference between the heated and nonheate 
groups. 
In comparing the chemotactic ability of normal serum to 
PPS, the chambers were sampled at 8 hr and the cells counted. 
The cell counts in the 2 different groups are pooled and shown 
in Fig 4 with the 95% confidence limits about the means. The 
mean cell chamber counts and ,95% confidence limits ·for th~ 
normal serum group are 1.3 X 106 ± .71 X 10", and for the PP 
group are .16 X 10" ± .13 X 106 PMN/chamber/8 hr. 
A Student t-test with Dr = 7 shows t = 4.45 and p < .01. It 
can be seen that the platelet depleted serum has been able to 
attract only about 12% as many cells as normal serum. 
Effects of heating serum 
8hr 24hr 
50% Autologous serum x = 4.1 X 10" 
S.D. = 4.4 X 10" 
x = 3.8 X 10" 
S.D. = 4.0 X 10~ 
50% Heated autologous 
serum 
x = 7.6 X 10" 
S.D. = 12.8 X 10" S .D~ : ~:~ ~ ~~:_ 
t-test 
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FIG 4 . Leukocyte migration of platelet poor serum versus norma 
serum. 
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FIG 5. Comparison of C5 depleted and platelet poor serum to that 
of a control serum that was albumin depleted then Zymosan activated. 
Note that either platelet depletion or C5 depletion removes approxi-
mately 90% of chemotactic activity. 
o 
z 
o 
<..:> 
o 
~ 
7 
6 
5 
GROUP MEANS AN D 95 0/0 CONF IDENCE LIMITS 
D 
ALBUMIN DEPLETED 
ZYMOSAN ACTIVATED 
SERUM 
p<O.OOl 
C 5 DEPLETED 
p> 0. 2 
ZYMOSAN ACTIVATED PLATELET 
SERUM POOR 
SERUM 
4~------------------------------__ __ 
FIG 6. Comparison of C5 depleted and platelet poor serum to albu-
min depleted serum for entire group of 8 patients. 
In the next experiment the in vivo role of C5 and its activation 
by Zymosan were evaluated. Blood agar cultures of all serum 
applied were negative. Figure 5 shows the results in each 
subject. The chambers filled with albumin-depleted Zymosan 
activated serum were considered to be maximally (100%) acti-
vated serum in each subject. Cell counts from the other cham-
bers are compared to this potential degree of chemotaxis. 
It was found that the C5-depleted Zymosan activated serum 
and the platelet poor serum generally possess between 1 % and 
20% of the chemotaxis potential of the maximally activated 
serum. 
Figure 6 illustrates the statistical analysis of pooled data in 
each of the 3 groups. The mean chamber cell counts and 95% 
confidence limits about the mean were 2.40 X 106 ± 1.1 x 106 
PMN/ chamber/ 8 hr for the albumin-depleted Zymosan acti-
vated serum, .30 X 106 ± .26 x 106 PMN/ chamber/ 8 hI' for the 
C5 depleted Zymosan activated serum, and .23 X 106 ± .19 x 
106 PMN/ chamber/ 8 hr for the PPS. 
It can be seen that compared to the albumin-depleted Zym-
osan activated group, the C5 depleted Zymosan activated group 
and the PPS group were only able to attract about 12% and 9% 
respectively as many cells. 
A t-test comparing the albumin-depleted Zymosan activated 
group with the C5 depleted Zymosan activated group and the 
PPS group were only able to attract about 12% and 9% respec-
tively as many cells. 
DISCUSSION 
The Boyden chamber and its modified analogs have been 
used widely to demonstrate the ability to encourage or discour-
age directional leukocyte movement. The technique, used here, 
with tape-stripping the stratum corneum and subsequent ap-
plication of a plastic chamber filled with the patient's autolo-
gous serum may be considered to simulate the human physio-
logic situation. The relative contribution of chemotactic factors 
identified in vitro can thus be evaluated in vivo. 
Kinetic studies demonstrate that the major leukocyte migra-
tion occurs in the first 8 hI' in this system. This has also been 
observed in other techniques involving skin abrasion [4]. Fur-
ther, leaving the chambers in place for only 8 hr offers the 
additional advantage of reducing the opportunity for bacterial 
overgrowth. Dilution of autologous serum to 10% or less reduces 
its potency as an attractant. Therefore, a recommended modi-
fication of the original method is to use 50% autologous serum 
diluted in HBSS in each of duplicate chambers, assaying the 
contents of the chambers and removing them after 8 hr. 
No difference in leukocyte attraction was seen between 
heated and nonheated autologous serum. This would imply 
that the chemotactant in the serum is not heat labile. 
Weksler and Coupal [20] have identified degranulating plate-
lets during normal clotting as the critical source of enzymatic 
generation of chemattractant. By removing platelets prior to 
the degranulation during clotting, they were able to virtually 
abate the in vitro chemotactic activity of normal serum. Fur-
thermore, they were able to isolate an acid extractable protein, 
presumably an enzyme, from plateletlysosomes which was able 
to generate chemotactic activity in platelet poor serum and 
purified C5, but not C3. 
This study provides in vivo corroboration. Depleting plasma 
of platelets prior to clotting diminishes its potency in vivo as a 
chemattractant by almost 90% when compared to normally 
clotted serum. This suggests that without platelets, enzyme 
dependent generation and degranulation in vivo primarily occur 
intravascularly at the sites of endothelial injury. In vascular 
injury, this mechanism may be an important initiator of the 
neutrophilic inflammatory response. 
The depletion studies illustrate the predominant role of C5 
and its activated product, C5a as the principle chemattractant 
in normal clotted serum. When nonactivated platelet poor 
serum was subjected to mono specific irnmunoabsorption of C5 
with anti-C5, 90% of its chemotactic activity was lost. Thus, 
even the subsequent attempt at its activation with Zymosan 
failed to generate significantly more chemotactic activity than 
nonactivated platelet poor serum control. In contrast, platelet 
poor serum which was depleted of albumin by similar mono-
specific immunoabsorption as a control, was capable of being 
activated by Zymosan. Presumably, the continued presence of 
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C5 enabled chemotaxis generation to proceed normally. It is 
also seen that in the absence of C5 and its activated product, 
only about 10% of the chemotaxis potential of serum remains. 
It is thus likely that C5, presumably through its enzymatic 
cleavage to C5a, accounts for approximately 90% of the chem-
otaxis potential in normal human serum. The remainder may 
be accounted for by the various other blood proteins implicated 
in chemotaxis in vitro. 
We thank Roberta Dustin, Kathleen Wanda and Jacqueline Manning 
for their expert technical assistance and Sally Robben for preparation 
of the manuscript. 
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